Merck to acquire Terns Pharmaceuticals for $6.7B
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.7 billion. This marks Merck's third multibillion-dollar acquisition in the past year as the company looks to strengthen its portfolio ahead of its top-selling cancer drug Keytruda losing patent protection in 2028.
Terns Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:TERN)
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 9,767 call options on the stock. This represents an increase of 501% compared to the typical volume of 1,624 call options. Terns Pharmaceuticals Price Performance NASDAQ: TERN opened at $46.52 on Friday. The business has a
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?
The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again
Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated superior major molecular response rates versus Novartis' Scemblix, with robust safety and efficacy in heavily pre-treated CML patients. Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts.
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Terns Pharmaceuticals, Inc. (NASDAQ:TERN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Amy Burroughs - CEO & Director Scott Harris - Chief Development Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Thanks, everybody, for joining us.
Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript
Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript Company Participants Amy Burroughs - CEO & Director Emil Kuriakose - Chief Medical Officer Scott Harris - Chief Development Officer Conference Call Participants Ritu Baral - TD Cowen, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Eliana Merle - UBS Investment Bank, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good day, and thank you for standing by.
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (TERN -3.86%).
